OncoMatch/Clinical Trials/NCT07205536
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Is NCT07205536 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Mecapegfilgrastim and Oral or short-acting granulocyte-stimulating agents for myelosuppression.
Treatment: Mecapegfilgrastim · Oral or short-acting granulocyte-stimulating agents — This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07205536 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify